Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96